title: Clinical importance and representation of toxigenic and non-toxigenic Clostridium difficile cultivated from stool samples of hospitalized patients.
abstract: The aim of this study was to fortify the clinical importance and representation of toxigenic and non-toxigenic Clostridium difficile isolated from stool samples of hospitalized patients. This survey included 80 hospitalized patients with diarrhea and positive findings of Clostridium difficile in stool samples, and 100 hospitalized patients with formed stool as a control group. Bacteriological examination of a stool samples was conducted using standard microbiological methods. Stool sample were inoculated directly on nutrient media for bacterial cultivation (blood agar using 5% sheep blood, Endo agar, selective Salmonella Shigella agar, Selenite-F broth, CIN agar and Skirrow's medium), and to selective cycloserine-cefoxitin-fructose agar (CCFA) (Biomedics, Parg qe tehnicologico, Madrid, Spain) for isolation of Clostridium difficile. Clostridium difficile toxin was detected by ELISA-ridascreen Clostridium difficile Toxin A/B (R-Biopharm AG, Germany) and ColorPAC ToxinA test (Becton Dickinson, USA). Examination of stool specimens for the presence of parasites (causing diarrhea) was done using standard methods (conventional microscopy), commercial concentration test Paraprep S Gold kit (Dia Mondial, France) and RIDA(®)QUICK Cryptosporidium/Giardia Combi test (R-Biopharm AG, Germany). Examination of stool specimens for the presence of fungi (causing diarrhea) was performed by standard methods. All stool samples positive for Clostridium difficile were tested for Rota, Noro, Astro and Adeno viruses by ELISA - ridascreen (R-Biopharm AG, Germany). In this research we isolated 99 Clostridium difficile strains from 116 stool samples of 80 hospitalized patients with diarrhea. The 53 (66.25%) of patients with diarrhea were positive for toxins A and B, one (1.25%) were positive for only toxin B. Non-toxigenic Clostridium difficile isolated from samples of 26 (32.5%) patients. However, other pathogenic microorganisms of intestinal tract cultivated from samples of 16 patients. Examination of cultivated colonies revealed that most of cultivated species belonged to genera of Campylobacter spp., Salmonella spp., and Candida spp.. In control group, toxigenic Clostridium difficile cultivated from stool samples of two patients (2%) and non-toxigenic Clostridium difficile from samples of five patients (5%). This research confirmed clinical importance of toxigenic Clostridium difficile found in liquid stool samples of hospitalized patient, and the possibility of asymptomatic carriage in 2% of patients with formed stool.
authors.affiliation: Faculty of Medicine, University of Nis , Serbia ; Institute for Public Health Nis, Center of Microbiology , Serbia.
authors.forename: Stojanovic
authors.initials: S
authors.lastname: Predrag
authors.forename: Kocic
authors.initials: K
authors.lastname: Branislava
authors.forename: Stojanovic
authors.initials: S
authors.lastname: Miodrag
authors.forename: Miljkovic-Selimovic
authors.initials: MS
authors.lastname: Biljana
authors.forename: Tasic
authors.initials: T
authors.lastname: Suzana
authors.forename: Miladinovic-Tasic
authors.initials: MT
authors.lastname: Natasa
authors.forename: Babic
authors.initials: B
authors.lastname: Tatjana
keywords: Clostridium difficile; diarrhea; toxins
references.citation: Clin Microbiol Infect. 2007 Nov;13(11):1058-64
references.pmid: 17922780
references.citation: Clin Microbiol Infect. 2006 Oct;12 Suppl 6:2-18
references.pmid: 16965399
references.citation: Diagn Microbiol Infect Dis. 2002 Jul;43(3):189-92
references.pmid: 12106951
references.citation: Postgrad Med J. 1993 Jan;69(807):45-7
references.pmid: 8446550
references.citation: J Clin Microbiol. 2002 Jun;40(6):2079-83
references.pmid: 12037068
references.citation: Br Med J. 1977 May 14;1(6071):1246-8
references.pmid: 861560
references.citation: Can Commun Dis Rep. 1999 Apr 1;25(7):65-9
references.pmid: 10344088
references.citation: Clin Microbiol Infect. 2005 Jul;11 Suppl 4:57-64
references.pmid: 15997485
references.citation: Kansenshogaku Zasshi. 2004 Apr;78(4):312-9
references.pmid: 15176235
references.citation: Eur J Clin Microbiol Infect Dis. 2003 Sep;22(9):525-9
references.pmid: 12938013
references.citation: J Antimicrob Chemother. 1998 May;41 Suppl C:13-9
references.pmid: 9630370
references.citation: Anaerobe. 2003 Dec;9(6):289-94
references.pmid: 16887714
references.citation: Diagn Microbiol Infect Dis. 2005 Jun;52(2):153-5
references.pmid: 15964504
references.citation: Anaerobe. 2005 Oct;11(5):258-61
references.pmid: 16701581
references.citation: Int J Infect Dis. 2007 Jan;11(1):5-10
references.pmid: 16857405
references.citation: J Med Microbiol. 2008 Jun;57(Pt 6):697-701
references.pmid: 18480325
references.citation: Korean J Intern Med. 2008 Mar;23(1):9-15
references.pmid: 18363274
references.citation: Anaerobe. 2003 Jun;9(3):113-6
references.pmid: 16887697
references.citation: Compr Ther. 1993;19(4):151-6
references.pmid: 8261769
references.citation: J Clin Microbiol. 1998 Jan;36(1):184-90
references.pmid: 9431944
references.citation: Am J Infect Control. 1986 Jun;14(3):99-109
references.pmid: 3524319
references.citation: J Hosp Infect. 1999 Jul;42(3):248-9
references.pmid: 10440000
references.citation: Curr Top Microbiol Immunol. 2000;250:109-25
references.pmid: 10981360